Bayer's $7.25 billion Roundup settlement faces new objections - Reuters

Bayer proposed $7.25 billion settlement aimed at resolving the vast majority of future Roundup cancer claims is now facing significant pushback, particularly from the law firm Keller Postman. Objectors are challenging the deal in the U.S. District Court for the Eastern District of Missouri, citing a "lack of adversity" in the negotiation process, which they argue fails to adequately protect the interests of absent class members. This legal skirmish threatens to further delay Bayer efforts to put an end to the protracted Multi-District Litigation (MDL) surrounding its controversial glyphosate-based herbicide. This ongoing saga underscores the immense financial and reputational headwinds Bayer has faced since its 2018 acquisition of Monsanto, a deal that effectively saddled the German pharmaceutical and life sciences giant with colossal long-tail liabilities associated with Roundup. The objections highlight the complexities of mass tort litigation and the critical importance of robust corporate due diligence, especially when integrating potentially toxic assets. In the current global macroeconomic climate, where corporate balance sheets are scrutinized amid persistent inflation and supply chain fragilities, such multi-billion-dollar legal payouts and their inherent uncertainties can significantly impact investor confidence and future capital allocation strategies across the agrochemical industry.